Stockreport
Edwards Lifesciences raises FY26 guidance following strong Q1 [Yahoo! Finance]
Last edwards lifesciences corporation earnings: 4/23 04:15 pm
Check Earnings Report
US:NYSE Investor Relations: ir.edwards.com
The medtech giant reported revenues of around $1.65bn in Q1, driven by steady double-digit growth across its portfolio. With the percentage uplift for the full year, Edwards now anticipates sales of $6.5bn to $6.9bn, with earnings mooted to fall in the $2.95 to $3.05 per share range, up from $2.90 to $3.05 previously. Edwards released its Q1 results after the market closed on 23 April. The company's shares on the New York Stock Exchange (NYSE), correct as at 12pm BST on 24 April, were up by over 2% at $81.51, versus $79.72 at market close on the prior day. Edwards transcatheter aortic valve replacement (TAVR) business pulled in the majority of the quarter's sales at around $1.2bn, representing a year-over-year (YoY) growth rate of 14.4%. GlobalData analysis reveals that the TAVR market is projected to reach a valuation of $14.9bn in 2034, up from $6.8bn in 2024. Further data from GlobalData indicates that Edwards currently holds $4.53bn in revenue in the TAVR space, with a US m
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | EW | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
EW alerts
EW alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
EW alerts
High impacting Edwards Lifesciences Corporation news events
Weekly update
A roundup of the hottest topics
EW
NEWS
NEWS
- Edwards Lifesciences (EW) was given a new $90.00 price target by Truist Financial Corporation.[MarketBeat]
- Edwards Lifesciences (EW) was given a new $85.00 price target by Canaccord Genuity Group Inc..[MarketBeat]
- Edwards Lifesciences (EW) had its "outperform" rating reaffirmed by Evercore Inc.[MarketBeat]
- Edwards Lifesciences (EW) had its price target raised by Robert W. Baird from $85.00 to $87.00. They now have a "neutral" rating on the stock.[MarketBeat]
- Edwards Lifesciences (EW) had its price target raised by BTIG Research from $98.00 to $100.00. They now have a "buy" rating on the stock.[MarketBeat]
- More
EW
SEC Filings
SEC Filings
- 4/23/26 - Form 8-K
- 4/9/26 - Form 4
- 4/6/26 - Form 4
- EW's page on the SEC website
- More